Why did Vexev raise $8.6 million?

Vexev raised $8.6 million to fund regulatory clearance with the US Food and Drug Administration and support commercialisation of its imaging platform. The proceeds will accelerate the clinical development of its automated technology.

What are the financial details of the Vexev funding round?

Vexev secured $8.6 million in new capital from venture capital funds including TreeArc Investment Group, TEN13, Bioshore Ventures, Alumni Ventures, Blackbird Ventures, Neotribe Ventures, Startmate, and Horizon. The capital injection increases total funding for Vexev to $27 million.

How is Vexev planning to use its technology in healthcare?

Vexev expects to deploy its imaging technology to automate non-invasive vascular imaging, starting initially with upper-limb care for dialysis patients. The company forecasts that its platform will allow clinicians to deliver faster, consistent diagnostic decisions across broader vascular diseases.

What does the Vexev technology platform do?

Vexev built its VxWave imaging platform by combining robotics, artificial intelligence, and ultrasound technology to create a new category of tomographic imaging. The automated system non-invasively captures high-quality vascular scans without requiring a specialist on site.

How does this raise impact the market positioning of Vexev?

Vexev remains an unlisted private company, meaning its valuation and share price are not publicly traded on a stock exchange. The company expects the new capital and backer support to advance its progression toward regulatory approval and market entry in the medical technology sector.

Health

Image for illustrative purposes only. Not a real photo.

Vexev raises $8.6M for medical imaging platform

Written by Heidi Cuthbert Published Aug 7, 2026, 3:30 AM

Medical technology startup Vexev has secured $8.6 million in new capital to accelerate commercial development.
The funding round brings the private company's total capital raised to $27 million.
The proceeds will support regulatory clearance and clinical application of its automated ultrasound platform.

Medical technology startup Vexev has raised $8.6 million to fund regulatory clearance for its automated imaging platform.

The new investment capital increases the Sydney-based company's total funding to $27 million.

"We believe high-quality vascular imaging should be available wherever patients receive care," said Vexev CEO John Carroll.

The company stated that the platform is initially being developed for upper-limb vascular imaging in dialysis patients.

The technology combines robotics, artificial intelligence, and ultrasound to automate non-invasive medical imaging processes.

New investors TreeArc Investment Group, TEN13, Bioshore Ventures, and Alumni Ventures backed the funding round.